Daiichi Sankyo joins norovirus vaccine race through UMN alliance | PharmaBoardroom
written on 17.02.2014
Tags:
,

Daiichi Sankyo joins norovirus vaccine race through UMN alliance

TAGS: ,

UMN will exclusively provide to its new partner a recombinant virus-like particle (VLP) antigen produced using baculovirus expression vector technology UMN has licensed for Asia from the US firm Protein Sciences. Daiichi Sankyo will carry out basic…

Latest Report